Screening by MMR-IHC with additional testing for the BRAF V600E variant can help to exclude sporadic MSI-H CRC in some cases (Fig. 17) and narrow down the target genes for genetic testing, making it more cost-effective than MSI testing [418]. This evidence concerns the gene BRAF and colorectal carcinoma.